Abstract:

Objective To investigate the expression of urinary soluble CD163 levels in patients with sys⁃ temic lupus erythematosus（SLE）and lupus nephritis（LN），as well as its disease activity and outcome correlation with LN. Methods LN，SLE patients from Jiujiang First People′s Hospital and a healthy control population were tested for CD163 levels at baseline and 3，6，and 12 months later. The relationship between urinary CD163 levels and the degree of proteinuria，clinical activity，disease outcome，pathological type，and immunological indicators were analyzed. The ROC curve assessed the predictive value of urinary CD163 levels for LN. Logisitic multiple regression analysis of the effect of urinary CD163 levels on complete response in LN patients. Results The urinary CD163 level in LN patients was significantly higher than that of active SLE，inactive SLE and non⁃LN glomerular disease，and the clinical severity and pathological type of the disease also varied（P < 0.001），and Urinary CD163 response gradually decreases along with the immune response（P < 0.001）. The area under the ROC curve for urinary CD163 level was 0.971（P < 0.001），> 98.5 ng/mmol with 85.7% sensitivity and 96.4% specificity. After adjusting for gender，age，uPCR，eGFR，C3，urinary CD163 & lt；205 ng/mmol was found to be an inde⁃ pendent predictor of 12 months of clinical remission in LN patients（OR = 2.173，P = 0.021）. Conclusion Urinary CD163 expression in LN is related to clinical activity and treatment outcome ，and it is a novel and valuable active biomarker. 

Key words:

lupus nephritis, CD163, urine, ROC curve, biomarker